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Background: Clinical observations and molecular analysis of the SMPD1 gene in Chinese patients with acid
sphingomyelinase deficiency Niemann-Pick disease (NPD) are scarce.
Methods: A cohort of 27 Chinese patients diagnosed with acid sphingomyelinase deficiency, within the past five
years, were collected and investigated for genotype, phenotype, and their correlations.
Results: The majority of our patients (25/27) were under 18 years of age. From the cohort group, eight (30%)
fulfilled characters of type A. Four other patients experienced neurologic involvement after two years of age, these
were classified as intermediate type. The remaining fifteen presented without clear neurologic involvement and
were regarded as type B. One patient, from the type B group, presented with the unusual symptom of a secondary
amenorrhea. Three patients, one from the type B group and two from the intermediate group, presented with
pronounced proteinuria, in the late stages of the disease, indicating possible kidney involvement in NPD.
Twenty-four SMPD1 gene mutations had been identified; eighteen of these are novel ones. These included four
exonic small deletions/duplications (c.4delC, c.147_150del4, c.842-849dup8, c.1307-1312dup6), one termination
mutation (p.Glu248X), and thirteen exonic point mutations (p.Gly336Ser, p.Trp342Cys, p.Leu382Phe, p.Pro429Leu, p.
Pro430Ser, p.Trp437Arg, p.Thr451Pro, p.His461Pro, p.Ala484Val, p.Ser486Arg, p.Tyr500His, p.Pro533Leu, p.Val559Leu).
Notably, eight mutations had more than one occurrence with c.4delC and p.Glu248X accounting for ~30% of all
alleles. Correlation analysis of genotype and phenotype indicated eight mutations, c.842-849dup8, p.Glu248X, p.
Arg230Cys, p.Trp437Arg, p.His461Pro, p.Ala484Val p.Ser486Arg, and p.Pro533Leu,to be severe mutations. Five
mutations, c.4delC, p.Leu382Phe, p.Pro429Leu, p.Pro430Ser and p.Val559Leu were projected to be mild mutations.
Interestingly, three intermediate individuals carried combinations of a mild mutation, c.4delC, on one allele and a
severe mutation on the other allele.
Conclusions: The Chinese population may have a comparably high incidence of sphingomyelinase-deficient
Niemann-Pick disease type A. This study has identified some novel genotype and phenotype correlations in this
rare and devastating disorder.Background
Acid sphingomyelinase (ASM) deficient Niemann-Pick
disease (NPD) is caused by SMPD1 gene mutations and
subsequent acid sphingomyelinase deficiency. It is a rare
autosomal recessive disorder, usually categorized as either
neuropathic type A (OMIM: 257200), non-neuropathic* Correspondence: huiwenzhang@yahoo.com; gu_xf53@yahoo.com.cn
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reproduction in any medium, provided the ortype B (OMIM: 607616), or clinically intermediate type
[1]. Affected individuals, with the neuropathic type A,
present with grossly enlarged spleens and livers, and di-
sease onset at approximately 3 months of age. These indi-
viduals also suffer psychomotor development retardation,
as evidenced by only achieving milestones of less than a
1-year developmental level, and death occurring at around
three years of age. Individuals with type B usually have
normal neurological development, and onset of the di-
sease can occur from infancy to late adulthood [2]. In
addition to types A and B, an intermediate form exists,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mality and onset at 2 to 7 years of age [3].
Occurrence of Niemann-Pick disease type B (NPD-B) is
pan-ethnic, while the people of Ashkenazi Jewish descent
have a high incidence of NPD-A. The genotype and
phenotype correlation for some mutations are consistent,
e.g., three common mutations, p.Arg498Leu (p.R496L),
p.Leu304Pro (p.L302P), and p.Phe333SerfsX52 (990delC),
account for approximately 90% of Niemann-Pick disease
type A alleles in the Ashkenazi Jewish population [4]. A
common NPD type B mutation, p.Arg610del (R608del),
has been reported to be the predominant mutant allele
(87%) in Maghreb region of North Africa [5]. A high fre-
quency of this mutation has also been found in Spain
(38%) [6], and in a report including patients from Euro-
pean countries, USA and Brazil (25%) [2]. In a worldwide
study this mutation accounted for 12% of allelic variation
[7]. In another study the p.Gln294Lys (Q292K) mutation
was associated with severe and progressive neurological
involvement in an intermediate type group [3]. Finally, the
p.Trp32X mutation was the most frequent allele identified
in an Italian NPD-B cohort study [8].
Currently, the mainstay treatment for Niemann-Pick
disease type A/B is symptomatic. Bone marrow trans-
plantation has been performed on a small number of
NPD patients and found to be beneficial only to NPD-B
individuals [9]. Enzyme replacement therapy in type B
has completed phase I clinical trial. A phase II clinical
trial should start in the near future. Accurate prediction
of disease type from genotype would be critical for opti-
mal treatment choices when a clinical phenotype cannot
be determined based on patients’ disease presentation.
Data from hundreds of North American, Western
European, and Ashkenazi Jewish patients are available.
Conversely, data from Chinese patients is rare [1]. In the
past 5 years, 27 patients with acid sphingomyelinase defi-
ciency were diagnosed at our center. Here we described
their genotypes and compared them with each phenotype
to determine any correlations. To date this is the largest
mutation profile report on Chinese NPD-A/B patients.
Methods
Consent
This study was carried out with approval from the Institu-
tional Review Ethics Board of Shanghai Xinhua Hospital,
Shanghai Jiao Tong University School of Medicine. In-
formed and written consent for the collection of samples
was obtained from guardians (for patients under 18 years of
age) or adult patients (18 years of age and above).
Clinical observations
Clinical information involving the symptoms at onset
and progression till first examination at the Endocrino-
logy and Genetic Metabolism clinic in Xinhua Hospitalwas gathered from interviews with parents and from
patients’ original medical charts. Special attention was
paid tomost the commonly occurring symptoms/conditions,
such as hepatosplenomegaly, gain/loss in psychomotor de-
velopmental milestones, diarrhea, recurrent respiratory in-
flammation, and blood chemistry panels. Onsite physical
examinations consisted of general and neurological examina-
tions, including anthropometric parameters. Retina exami-
nations were not conducted. Patient histories, physical
examinations and follow-ups were performed by at least one
of the authors.
Subjects
All subjects were from unrelated families and their par-
ents had no consanguinity. The diagnosis of acid sphin-
gomyelinase deficient Niemann-Pick disease in the
majority cases was based on clinical presentations and a
low level of ASM activity in peripheral leucocytes. One
individual, case 7, was clinically diagnosed by presenta-
tion and the detection of Niemann-Pick cells in her bone
marrow. The diagnosis was confirmed to be ASM defi-
ciency post mortem; both of her parents were found to
carry a “hot” mutation in the SMPD1 gene.
ASM activity measurement
Homogenates of leukocytes from patients’ peripheral blood
were used to measure ASM activity as previously reported
with minor modification [10]. Briefly, leukocytes, isolated
from blood cell lysates, were stored at −80°C until analysis.
Upon thawing samples were homogenized by sonication.
Homogenates were incubated for 17 hours, at 37°C
with 1.35 mM 6-hexadecanoylamino-4-methylumbelliferyl-
phosphorylcholine (purchased from MOSCERDAM sub-
strates) at pH 5.2. The reaction was stopped using 0.5 M
NaHCO3, 0.5 M Na2CO3, and 0.25% Triton X-100 at pH
10.7. A 4- methylumbelliferyl standard was used. The
fluorescence signals were read at the excitation wave-
length 404 nm and the emission wavelength 460 nm. Pro-
tein levels were determined using the Bio-Rad BCA
protein assay kit. The normal range of ASM activity is
13.7-86.1 nmol/17 h/mg protein with mean ± SD 47.2 ±
20 nmol/17 h/mg protein.
Sequencing of genomic DNA
Genomic DNA was extracted from peripheral blood using
the RelaxGene blood DNA isolation kit (DNA DP319-01,
Tiangen Biotech Co. Ltd., Beijing, China) according to the
manufacturer’s protocol. All exons and flanking regions of
the SMPD1 gene were amplified using 4 primer pairs (P1F
50agaagggtaatcgggtgtcc30, P1R 50tagatgccaccctctccatc30; P2F
50tggaaatggaggcccaag, P2R 50ttaggggagccaaatgaaga30; P3F
50actgtgagctccttgcaggt30, P3R 50tgctcaagggaattttcagc30; P4F
50ggggaggctcctcactagaa30, P4R agctccaggaaaggagaagg30) and
sequenced bi-directionally. The obtained sequences were
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to identify mutations and/or variations. In most cases,
patients’ parental DNA samples were analyzed to establish
the variation origin.
RNA expression of SMPD1 gene
To study the pathogenic effects of a variation in SMPD1
intron 5, from patient number 8, IVS5+5G>C, RNA was
extracted from peripheral blood stored in a PAXgene™
blood RNA tube (Qiagen) as previously reported [11].
RNA was reverse transcribed with PrimeScript RRTase
(TaKaRa, Japan) and amplified with two primer pairs
(P5F 50cgtcacagcacttgtgagga30, P5R 50ccaggattaaggccgatg
ta30; P6F 50atcggccttaatcctggttac30, P6R 50 ggctttttcaccct
ttcctac30) with the products sequenced bi-directionally.
Results
According to the NPD-A/B classification criteria [3],
8 individuals were assessed as type A and 4 as suffering
from the intermediate form. The remaining 15 individuals,
including 5 patients under 2 years of age, free of neuro-
logic impairment, were classified as type B (Table 1). The
possibility does exist that a few type B patients may
devolve into the intermediate type. Type A patients
accounted for 30% of the study group. In accordance with
previous findings, hepatosplenomegaly was detected in all
patients. Mildly elevated levels of hepatic transaminases
and triglycerides, along with chronic diarrhea, were also
common clinical findings. Two intermediate patients
(number 9 and 10) and one type B patient (number 25)
were in critical condition, presenting with a pot belly, asci-
tes, pitting edema on lower extremities, hypoproteinemia,
and proteinuria. These symptoms indicate possible kidney
involvement associated with late stages of the disease.
In this study, biallelic mutations were detected in
twenty-three patients and only one mutant allele could be
identified in 3 patients (number 8, 11, 25) (Table 1). No
mutation in the SMPD1 gene was detected in one patient
(number 21), although twice assay of ASM activity from
different preparation of her peripheral leucocytes had been
carried out to confirm its deficiency. Several mutations,
including small exon deletions (c.4delC, c.147-150del4),
duplications (c.1307-1312dup6, c.842-849dup8), small
insertion (c.1095_1096insG), and termination mutation
(p.Glu248X), resulting in premature stop codon and ren-
dering the enzyme noncatalytic, were considered to be
pathologic. Novel and recurrent point variations, such as
p.Leu382Phe, p.Ala484Val, and p.Ser486Arg were also
regarded as pathologic. For those novel and private varia-
tions, their pathogenicities were assessed using PolyPhen-2
(http://genetics.bwh.harvard.edu/pph2/index.shtml).
Nine of them, p.Gly336Ser, p.Trp342Cys, p.Pro429Leu,
p.Pro430Ser p.Trp437Arg, p.Thr451Pro, p.His461Val,
p.Tyr500His, and p.Pro533Leu, were predicted to have amaximum damaging effect score and presumed to be
pathological. The variation p.Val559Leu was predicted to
be benign, with a score of 0.22. Considering its presence in a
type B patient (number 18) with a severe mutation,
p.Ser486Arg (presented below), it was regarded as a muta-
tion withmild effect.
An intron variation, IVS5+5G>C, derived from a paternal
allele was identified in patient number 8. To investigate its
pathological influence in this patient, RNA was extracted
and analyzed for SMPD1 gene expression. The result
apparently showed patient 8 exclusively expressed his ma-
ternal allele carrying a p.His461Val mutation (Figure 1,
Panel A), and IVS5+5G>C variation did not have any ob-
servable impact on RNA splicing (Figure 1, Panel B).
In this patient, the SMPD1 gene may be paternally
imprinted and the maternal allele preferentially expressed,
as reported previously [12]. Our inability to detect the mu-
tant IVS5+5G>C allele product could also be due to a pre-
mature stop codon and nonsense-mediated mRNA decay.
Further functional test, such as a mini-gene system, need
to be done to determine the pathogenicity of IVS5+5G>C
mutation. In total, at least 24 different mutations had been
found (Figure 2).
Three patients (number 15, 6, and 4) carried two se-
quence variations on a single SMPD1allele. In patient 15,
both p.Ser250Arg and p.Glu471Lys mutations were of ma-
ternal inheritance. Previously, the p.Ser250Arg mutation
has been reported in combination with a premature stop
codon, in a Dutch patient with a mild form of type A
NPD [10]. In this study, we were unable to determine the
pathogenicity of p.Glu471Leu. Similarly, in patient 6, a
termination, p.Glu248X, and an exon point mutation,
p.Phe482Ser, were identified on the same allele. Another
variation at the same codon, p.Phe482Leu, had been docu-
mented in a type B patient [7]. The nature of p.Phe482Ser
was unclear here. Another variation, p.Ala541Thr, was
identified on the same allele as p.Pro533Leu, in patient 4.
To fully understand the complete effects of these three
variations, expression studies need to be conducted as pre-
viously reported [10].
It is very interesting that with the exception of five exon
point mutations, c.688C>T (p.Arg230Cys) [7], c.748A>
T(p.Ser250Arg) [13], c.759C>A (p.Asp253Glu) [14],
c.1565A>G (p.Asn522Ser) [10], c.1492C>T (p.Arg498Cys)
[15], and a small insertion, c.1095_1096insG [7], the
majority of mutations, including c.4delC, c.147_150del4,
c.1307-1312dup6, c.842-849dup8, p.Glu248X, p.Gly336Ser,
p.Trp342Cys, p.Leu382Phe, p.Pro429Leu, p.Pro430Ser,
p.Trp437Arg, p.Thr451Pro, p.His461Pro, p.Ala484Val,
p.Ser486Arg, p.Pro533Leu, p.Val559Leu and p.Tyr500His,
were novel according the SMPD1 gene mutation database
(http://www.hgmd.cf.ac.uk). These newly detected muta-
tions have been deposited in the public databases dbSNP,
with the batch accession number 1057561.
Table 1 Clinical and molecular data of 27 Chinese patients with acid sphingomyelinase-deficient NPD










1 A male 1y 1 m HP, PR, diarrhea, RG, death at





E2 / E2 0




E2 / E5 0
3 A female 11 m 5 m HP, PG, RG, anemia, leucocytopenia,





E2 / E2 2.3
4 A male 1y4m 5 m HP, hypotonia,diarrhea, elevated TG,







E4 / E6 4.9






E2 / E2 1.7
6 A female 3 m after
birth






E2 / (E2;E5) 0.6




E2 / E5 unknown
8 A male 1y4m 6 m diarrhea, HP, hypotonia, PR [c.1382A>C]
+[IVS5+5G>C]
p.His461Pro E5 3.5
9 intermediate male 7y 7 m HP, RG, SS, MR at age 5, ascites,





E1 / E2 3.6
10 intermediate male 5y 2y HP, SS, RG, anemia, leucocytopenia,
ascites, hypoproteinemia,MR at age





E1 / E2 3.4
11 intermediate female 8y 8y HP, moderate MR c.1458T>G p.Ser486Arg E5 1.2




E1 / E5 3.8




E2 / E4 0




E2 / E5 0














E3 / E6 3.1




E1 / E1 3.6




E5 / E6 5.6




E6 / E6 7.3





21 B female 3y 1y HP, microproteinuria undetected 2.4
22 B female 3y7m after
birth




E1 / E1 4.8






E1 / E3 2




E1 / E1 1.4
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Table 1 Clinical and molecular data of 27 Chinese patients with acid sphingomyelinase-deficient NPD (Continued)
25 B female 12y 10 m HP, proteinuria, ascites, RG,
splenectomy at age 9, died at age
13
c.1006G>A p.Gly336Ser E2 4.9




E4 / E5 3.1






E4 / E6 3
Note: HP indicated hepatosplenomegaly, PR indicated psychomotor regression, RG indicated mildly raised GPT and GST, PF indicated positive family history, RR
indicated recurrent respiratory tract infection, SS indicated short stature, MR indicated mental regression. P indicated patient number, and E indicated exon. The
mean ± SD of ASM activity was 47.2 ± 20 nmol/17 h/mg protein (range: 13.7 to 86.1).
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p.Glu248X, p.Ser486Arg, p.Asn522Ser, p.Leu382Phe,
p.Arg230Cys, and p.Ala484Val, occurred more than once
and accounted for 61.1% of all disease alleles (Table 2).
The two most frequent mutations were c.4delC and
c.842-849dup8 and consisted of 29.6% of the total alleles.
Two recurrent mutations, c.842-849dup8 and p.Glu248X,
are presumed to cause premature stop codon and are con-
sidered severe mutations. In accordance with a severe
genotype, 3 individuals (number 1, 3, and 6) carrying a
combination of mutations with c.842-849dup8 on one allele
and p.Glu248X on the other, had typical type A presenta-
tion. Since both severe alleles are required to result in
NPD-A and at least one severe allele is required to in-Figure 1 Failed amplification of paternal allele of the SMPD1 gene in
heterozygous mutation, c.1382A>C, derived from her mother, as observed
apparently homozygous state. The panel B showed an intron variation IVS5
level exon 5 and 6 remained unbroken, indicating lack of amplification of ptermediate type NPD, p.Trp437Arg (in number 4),
p.Ala484Val (in number 2), p.Arg230Cys (in number 9),
p.His461Pro (in number 8), p.Ser486Arg (in patient 7 and
12), and p.Pro533Leu (in number 4) were estimated to be
severe mutations. In consideration that at least one mild
mutation is necessary to result in NPD-B, p.Pro430Ser (in
number 13), p.Val559Leu (in number 18), p.Leu382Phe
(in number 23), p.Pro429Leu (in number 26) were esti-
mated to be mild mutations.
Discussion
In the largest NPD database, at Mount Sinai School of
Medicine, ~20% presented with type A, of these 66%
were Ashkenazi Jewish [1]. Although NPD-A has a lowerpatient number 8. The panel A showed patient 8 carried a
on a DNA level. However, at the RNA level the expression was in an
+5G>C at the DNA level derived from this patient’s father. At the RNA
aternal allele.
Figure 2 Distribution of SMPD1 gene mutations from Chinese NPD-A/B patients. A total of 24 different mutations had been identified in
this Chinese patient cohort. The eight recurrent mutations are in red, and the presumed severe mutations are marked by blue pentagram.
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Jewish, it is still of notable occurrence. In this study,
there were only two patients (number 16 and 19) of
adult age, the rest ranged in age from 3 months to
12 years, with a mean age of 5.6 years. Therefore, these
finding could be biased with respect to patients’ age.
Beside the classical presentation discussed earlier
[2,16], growth restriction has been described in patients
with NPD-B [17]. In our observations, growth restric-
tions were more apparent in patients 5 years of age and
above. For example, patient 9, 10, 13 and 24 had Z
scores for height lower than −2, meeting the criteria of
short stature. Conversely, two adult patients (patient 16
and 19), with the p.Asn522Ser mutation, had normal
height. Patient 16, an adult, sought medical treatment
for secondary amenorrhea initially and was, only then,
diagnosed with NPD-B. Amenorrhea is rarely described
comorbidity with NPD-B [2]. From this data, we propose
the menstrual cycles of adult female NPD patients
should be observed.
Although NPD-B is a multi-system disease, kidney in-
volvement is rarely described. Imaging studies found
that the kidneys were enlarged by Niemann-Pick cells
infiltration [18]. In the end stages of an intermediate
NPD patient, kidney biopsies found foamy podocytes,
vacuolated tubular epithelial cells, and accumulation of
foam cells in the interstitium [19]. In this study, BTable 2 Genotype/phenotype correlation for 8 recurring muta
Mutation Exon Number of
Alleles
c.4delC 1 9 3 type B pat
c.842-849dup8 2 7 1 type A
c.742G>T (p.Glu248X) 2 4 3 type A pa
c.1458T>G (p.Ser486Arg) 5 4 2 type A patients in
c.1565A>G (p.Asn522Ser) 6 3 1 type B
c.1144C>T (p.Leu382Phe) 3 2
c.688T>C (p.Arg230Cys) 2 2 1 ty
c.1451C>T (p.Ala484Val) 5 2 1 type Aultrasonography identified abnormal signals in bilateral
adrenal pelvis and bilateral large kidney size in one patient
(number 13). Three other patients (number 9, 10, and 25),
in the late stages of the disease, presented with protein-
uria, hypoproteinemia, and ascites. In addition, patient 21
had microproteinuria. All these observations substantiate
kidney involvement in NPD.
In this study we found Chinese patients to be free of
“hot” mutations identified in other ethnicities, such as
p.Arg498Leu [20], p.Leu304Pro [21], p.Phe333SerfsX52
[22], p.Arg610del [23], p.Trp393Gly [24], and p.Q294K
[14]. Here, the recurrent mutations were novel, e.g.
c.4delC, c.842-849dup8, p.Glu248X, p.Leu382Phe,
p.Ser486Arg, p.Ala484Val. As a group, these muta-
tions accounted for 51.9% of all alleles.
With regard to phenotype/genotype correlations, c.842-
849dup8 was homozygous in one NPD-A patient (number
5), heterozygous in five other NPD-A patients (number 1,
2, 3, 6, and 7), and not present in any NPD-B patients,
thus c.842-849dup8 is considered a severe mutation. An-
other mutation, c.4delC, was found to be homozygous in
3 type B patients (17, 22, and 24) and heterozygous in 3
intermediate patients (9, 10, and 12). The oldest homozy-
gous c.4delC patient was 7 years of age and without
neurologic involvement (patient 24), which indicated
c.4delC is a non-neurotoxic mutation resulting in compara-
tively low severity of NPD. Interestingly, when consideringtion in Chinese patients
Phenotype
ients in homozygosity; 3 intermediate patients in heterozygosity
patient in homozygosity; 5 type A patients in heterozygosity
tients in heterozygosity; 1 intermediate patient in heterozygosity
heterozygosity;1 intermediate patient in heterozygosity; 1 type B patient
in heterozygosity
patient in homozygosity;1 type B patitent in heterozygosity
2 type B patients in heterozygosity
pe B patients in heterozygosity, 1 intermediate patient
patient in heterozygosity; 1 type B patient in heterozygosity
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produce a complete enzyme deficiency. However, we
observed it was associated with a mild form of the disease.
It has been previously reported that a second methionine
(Met33) can rescue mutations involving the traditional
start methionine [8], this may be occurring in the c.4delC
mutation as well.
The c.1565A>G (p.Asn522Ser) mutation resulted in
~10% of wild type activity and has been described previ-
ously in a NPD-B patient [10]. Both patients with homoal-
lelic (number 19) or heterallelic (number 16) p.Asn522Ser
were free of neurologic involvement. Additionally, the dis-
ease onset occurred in their adulthood and the patients
had normal statures, supporting the presumed mild na-
ture of the mutation.
Previous finding indicate that patients with the inter-
mediate phenotype carried at least one severe mutation
[8]. Here, three intermediate patients (number 10, 11, 12)
had one severe mutation, p.Glu248X and p.Ser486Arg
(twice occurring) respectively. Besides, three of four inter-
mediate patients had the common c.4delC (number 9, 10,
12), which was assumed to be a mild mutation. On this
basis, p.Arg230Cys was presumed to be a severe mutation
considering its presence with c.4delC in patient 9. The
combination of a severe mutation on one allele and a mild
mutation on the other allele indicates their intermediate
status both in clinical phenotype and genotype.
In conclusion, a high portion of Chinese NPD patients
have been diagnosed with type A. The SMPD1 gene mu-
tation profiles in Chinese patients are markedly different
from reported data of other ethnic groups. Two novel
mutations, c.4delC and c.842-849dup8 had significantly
high incidences in this cohort of patients. Our data pro-
vides novel genotype and phenotype correlation of ASM
deficiency and has important implications in genetic
counseling and in decisions regarding therapy for care
givers. In the future it may aid in large scale carrier
screening. One of the shortcomings of this study is that
all data comes from one hospital. For this rare disease,
data accumulated from multiple centers of China would
strengthen these observations.
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